Benjamin Edwards Inc. lifted its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 12.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 156,561 shares of the medical technology company’s stock after purchasing an additional 17,883 shares during the quarter. Benjamin Edwards Inc.’s holdings in Stryker were worth $43,126,000 at the end of the most recent reporting period.
Several other institutional investors have also recently bought and sold shares of the business. Gables Capital Management Inc. purchased a new stake in shares of Stryker during the 2nd quarter worth approximately $25,000. Kilter Group LLC bought a new stake in shares of Stryker in the 2nd quarter valued at about $25,000. Cornerstone Financial Management LLC increased its holdings in Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after purchasing an additional 31 shares during the period. Highland Investment Advisors LLC bought a new stake in shares of Stryker during the 2nd quarter valued at about $25,000. Finally, Compass Financial Management LLC purchased a new stake in shares of Stryker in the 2nd quarter worth about $27,000. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Price Performance
Shares of SYK opened at $309.91 on Friday. Stryker Corporation has a 1-year low of $267.00 and a 1-year high of $389.33. The company has a debt-to-equity ratio of 0.60, a current ratio of 2.18 and a quick ratio of 1.30. The firm has a market capitalization of $117.98 billion, a PE ratio of 33.00, a price-to-earnings-growth ratio of 2.13 and a beta of 0.78. The company’s fifty day moving average price is $295.66 and its 200-day moving average price is $321.39.
Wall Street Analyst Weigh In
A number of analysts have weighed in on the stock. Truist Financial restated a “hold” rating and set a $305.00 price objective (down from $310.00) on shares of Stryker in a research note on Monday, November 2nd. Deutsche Bank cut their price objective on shares of Stryker from $315.00 to $275.00 and set a “hold” rating for the company in a report on Friday, October 30th. Rothschild & Co Redburn lowered their price objective on shares of Stryker from $360.00 to $336.00 in a research report on Monday, November 2nd. Evercore increased their target price on shares of Stryker from $335.00 to $355.00 in a research note on Wednesday, October 28th. Finally, Wells Fargo & Company dropped their target price on shares of Stryker from $418.00 to $348.00 and set an “overweight” rating on the stock in a research note on Wednesday, September 9th. Twenty-one investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $343.77.
View Our Latest Analysis on SYK
Insider Buying and Selling at Stryker
In other news, Director Ronda Stryker sold 550,000 shares of the stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $325.32, for a total transaction of $178,926,000.00. Following the transaction, the director owned 1,701,375 shares in the company, valued at $553,491,315. This trade represents a 24.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 4.60% of the stock is currently owned by insiders.
Stryker Profile
Stryker is a medical technology company that develops and sells products and services for healthcare providers. Its offerings include orthopedic implants and surgical equipment, neurotechnology and spine products, and medical and surgical equipment used in hospitals and other care settings. The company’s products also include patient-handling and emergency medical equipment, as well as instruments and technologies that support surgical procedures. Stryker serves healthcare customers in the United States and internationally.
See Also
- Five stocks we like better than Stryker
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.
